Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis.

ABSTRACT:

Background/objectives

Elexacaftor, tezacaftor, and ivacaftor (ETI) have significantly improved lung function in people with cystic fibrosis (pwCF). Despite exceptional improvements in most cases, treatment-related inter-subject variability and drug-drug interactions that complicate modulator therapy have been reported.

Methods

This retrospective analysis presents data on the serum concentration of ETI in our pwCF with full or reduced dosage from August 2021 to December 2023 via routine therapeutic drug monitoring (TDM). The data were compared with the maximum drug concentrations (Cmax) from the pharmaceutical company's summary of product characteristics.

Results

A total of 786 blood samples from 155 pwCF (41% female, 59% male) were analyzed. The examinations were divi

SUBMITTER: Naehrig S 

PROVIDER: S-EPMC11508966 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature